Abstract TRAF3-interacting protein 3 (TRAF3IP3) is expressed in the immune system and
participates in cell maturation, tissue development, and immune response. In a previous …

Immune evasion is essential for carcinogenesis and cancer progression. Programmed death-
ligand 1 (PD-L1), a critical immune checkpoint molecule, interacts with programmed death …

Several preclinical studies demonstrate that antitumor efficacy of programmed cell death-1
(PD-1)/programmed death-ligand 1 (PD-L1) blockade can be improved by combination with …

Programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) is a significant
immune checkpoint, and the dysfunction of this axis contributes to tumor metastasis and …

With recent approvals for multiple therapeutic antibodies that block cytotoxic T lymphocyte
associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) in melanoma …

Immune checkpoint molecules play a pivotal role in the initiation, regulation, and termination
of immune responses. Tumor cells exploit these checkpoints to dampen immune cell …

In cancer-immunity cycle, the immune checkpoint PD1 and its ligand PDL1 act as
accomplices to help tumors resist to immunity-induced apoptosis and promote tumor …

TRAF3IP3 was reportedly associated with poor prognosis in patients with melanoma;
however, its role in glioma is unknown. We aimed to demonstrate the relationship between …

Immune checkpoint-blockade treatments targeting PD-1/PD-L1 have revolutionized cancer
therapy. Hence, understanding the regulation of PD-L1 expression has major clinical …

Checkpoint blockade through inhibition of programmed cell death protein 1 (PD1), which
enables tumours to evade the immune system, has radically changed the treatment and …